1GSN Stock Chart & Stats
€123.00
-€1.00(-0.81%)
At close: 4:00 PM EDT
€123.00
-€1.00(-0.81%)
Day’s Range― - ―
52-Week Range€84.50 - €150.00
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€4.53B
Enterprise Value€6.22K
Total Cash (Recent Filing)€718.65M
Total Debt (Recent Filing)€282.82M
Price to Earnings (P/E)90.5
Beta0.75
Next Earnings
Nov 10, 2026EPS Estimate
0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.59
Shares Outstanding37,817,770
10 Day Avg. Volume1
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-4.65
Price to Book (P/B)3.31
Price to Sales (P/S)4.44
P/FCF Ratio89.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€166.42Price Target Upside35.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)3.12
Revenue Forecast (FY)€914.16M
Bulls Say, Bears Say
Bulls Say
Organic Growth And Raised 2026 OutlookBroad-based organic growth and higher full-year guidance indicate sustained demand across Novanta’s OEM markets. Continued expansion, supported by design wins and customer production volumes, can improve operating scale and reinforce the company’s long-term growth trajectory.
Riverpoint Expands Recurring Medical RevenueRiverpoint adds a market-leading minimally invasive surgical consumables platform, increasing recurring revenue and medical content per customer system. Shared OEM relationships and expanded manufacturing capacity could broaden Novanta’s addressable market and strengthen its competitive position.
Innovation, Bookings And Cash GenerationStrong new-product adoption, bookings and cash conversion support the durability of Novanta’s differentiated technology portfolio. Vitality gains and healthy free cash flow provide resources for product development, integration and manufacturing improvements while validating earnings quality.
Bears Say
Higher Acquisition-related LeverageRiverpoint materially increases debt and interest obligations, reducing financial flexibility if integration or end-market growth underperforms. Although management expects deleveraging, the larger balance-sheet burden could constrain investment capacity and amplify execution risk over the next several quarters.
Medical And Consolidated Margin PressureLower medical margins from product mix, transformation costs and site rationalization indicate that revenue growth is not yet translating consistently into profitability. Sustained cost pressure or a heavier mix of lower-margin products could limit earnings conversion and reduce the benefits of scale.
Weakness In Precision Medicine And Life SciencesThe weakness reflects more than a temporary order fluctuation: management does not expect sustained precision-medicine growth in 2026, and life sciences faces commoditization. This creates a prolonged drag on mix, utilization and growth until recovery or portfolio actions materialize.
1GSN FAQ
What was Novanta Inc’s price range in the past 12 months?
Novanta Inc lowest stock price was €84.50 and its highest was €150.00 in the past 12 months.
What is Novanta Inc’s market cap?
Novanta Inc’s market cap is €4.53B.
When is Novanta Inc’s upcoming earnings report date?
Novanta Inc’s upcoming earnings report date is Nov 10, 2026 which is in 74 days.
How were Novanta Inc’s earnings last quarter?
Novanta Inc released its earnings results on Aug 05, 2026. The company reported €0.77 earnings per share for the quarter, beating the consensus estimate of €0.718 by €0.052.
Is Novanta Inc overvalued?
According to Wall Street analysts Novanta Inc’s price is currently Undervalued.
Does Novanta Inc pay dividends?
Novanta Inc does not currently pay dividends.
What is Novanta Inc’s EPS estimate?
Novanta Inc’s EPS estimate is 0.84.
How many shares outstanding does Novanta Inc have?
Novanta Inc has 37,817,770 shares outstanding.
What happened to Novanta Inc’s price movement after its last earnings report?
Novanta Inc reported an EPS of €0.77 in its last earnings report, beating expectations of €0.718. Following the earnings report the stock price went up 8.696%.
Which hedge fund is a major shareholder of Novanta Inc?
Currently, no hedge funds are holding shares in DE:1GSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novanta Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€166.42 (35.30% Upside)
€166.42 (35.30% Upside)
Blogger Sentiment
Neutral
DE:1GSN Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
41.59%
Trailing 12-Months
Company Description
Novanta Inc
Operating globally, Novanta Inc. and its affiliated companies specialize in the development, production, and distribution of advanced photonics, vision, and precision motion components and sub-assemblies. These highly engineered solutions are supplied to Original Equipment Manufacturers (OEMs) across the medical and industrial sectors. Within its Photonics division, Novanta provides a suite of laser-driven technologies. These encompass systems for laser scanning, beam manipulation, and various laser types such as CO2, solid-state, ultrafast, and optical light engines. Their applications span critical areas like industrial manufacturing, precision measurement (metrology), advanced imaging in healthcare and biological research, DNA sequencing, and specialized medical laser treatments. The Vision segment delivers an array of medical-grade innovations. This portfolio comprises instruments like medical insufflators, pumps, and their associated consumables, alongside comprehensive visualization tools. It also features wireless communication systems, video recording devices, and integration platforms designed for operating theaters. Further offerings include optical data acquisition, machine vision systems, radio frequency identification (RFID) solutions, thermal recording devices, spectrometry equipment, and integrated touchscreen displays. Furthermore, the Precision Motion division specializes in supplying components such as optical and inductive encoders, high-precision motors, servo drives, and complete motion control systems. This segment also delivers integrated stepper motors, sophisticated robotic end-effectors, air bearings, and air bearing spindles. Novanta distributes its extensive product lines through various channels, including its dedicated direct sales team, value-added resellers, distribution partners, and system integrators. These offerings are available under well-known brand names such as Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, NDSsi, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, Celera Motion, MicroE, Zettlex, Applimotion, Ingenia, and Westwind. Founded in 1968, the company operated as GSI Group, Inc. until its rebranding to Novanta Inc. in May 2016. Its corporate headquarters are located in Bedford, Massachusetts.
1GSN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was positive: management reported broad-based organic growth, margin expansion, strong cash generation, significant new product momentum, and closed an accretive strategic acquisition (Riverpoint) that raises guidance. There are manageable near-term headwinds — lower medical segment margins from mix and transformation costs, supply-chain/tariff pressures, integration and restructuring expenses, and a temporary rise in gross leverage from acquisition financing — but management provided clear plans and guidance to offset these over time. The highlights materially outweigh the lowlights.View all DE:1GSN earnings summaries1GSN Stock 12 Month Forecast
Average Price Target
€166.42
▲(35.30% Upside)










